Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes

Journal of Virology

Volumn 70, Issue 8, 1996, Pages 5203-5212

  Hanecak, Ronnie ^a   Brown Driver, Vickie ^a   Fox, Maureen C ^a   Azad, Raana F ^a   Furusako, Shoji ^a,c   Nozaki, Chikateru ^b   Ford, Clifford ^a,d   Sasmor, Henri ^a   Anderson, Kevin P ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b Chemo Sero Therapeutic Research Institute   (Japan)

^c MOCHIDA PHARMACEUTICAL CO   (Japan)

^d AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CAPSID PROTEIN; ENVELOPE PROTEIN; MEMBRANE PROTEIN; VIRUS RNA;

ARTICLE; GENE EXPRESSION REGULATION; GENE STRUCTURE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIVER CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; RIBOSOME; RNA ANALYSIS; VIRAL GENETICS; VIRUS GENE; VIRUS REPLICATION;

EID: 0029996016     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.8.5203-5212.1996     Document Type: Article

References (53)

1. Agrawal, S., J. Goodchild, M. P. Civiera, A. T. Thornton, P. M. Sarin, and P. C. Zamecnik. 1988. Oligodeoxynucleoside phosphoramidites and phosphorothioates as inhibitors of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 85:7079-7083.
2. Agris, C. H., K. R. Blake, P. S. Miller, M. P. Reddy, and P. O. P. Ts'O. 1986 Inhibition of vesicular stomatitis virus protein synthesis and infection by sequence-specific oligodeoxyribonucleoside methylphosphonates. Biochemistry 25:6268-6275.
3. Alt, M., R. Renz, P. H. Hofschneider, G. Paumgartner, and W. H. Caselmann. 1995. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology 22:707-717.
4. Alter, H. J., R. H. Purcell, J. W. Shih, J. C. Melpolder, M. Houghton, and Q.-L. Choo. 1989. Detection of antibody to hepatitis C virus in prospeclively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N. Engl. J. Med. 321:1494-1500.
5. Azad, R. F., V. B. Driver, K. Tanaka. R. M. Crooke, and K. P. Anderson. 1993. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob. Agents Chemother. 37:1945-1954.
6. Baker, B. F., S. Lot, T. Condon, S. Flourney, E. Lesnik, M. Graham, H. Sasmor, and C. F. Bennett. Unpublished data.
7. Bennett, C. F., M,-Y. Chiang, H. Chan, J. E. Shoemaker, and C. Mirabelli. 1992, Cationic lipids enhance cellular uptake and activity of phosphorothioate antiscnse oligonucleotidcs. Mol. Pharmacol. 41:1023-1033.
8. Brown, E. A., H. Zhang, L.-H. Ping, and S. M. Lemon. 1992. Secondary structure of the 5' nontranslatcd regions of hepatitis C virus and pestivirus genomic RNAs. Nucleic Acids Res. 20:5041-5045.
9. Bruix, J., J. M. Barrera, X. Calvet, G. Ercilla, J. Costa, J. M. Sanchez-Tapias, M. Ventura, M. Vall, M. Bruguera, C. Bru, R. Castillo, and J. Rodes. 1989, Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet ii:1004-1006.
10. Bukh, J., R. H. Purcell, and R. H. Miller. 1992. Sequence analysis of the 5́ noncoding region of hepatitis C virus. Proc. Natl. Acad. Sci. USA 89:4942-4946.
11. Bukh, J., R. H. Purcell, and R. H. Miller. 1993. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. Proc. Natl. Acad. Sci. USA 90:8234-8238.
12. Busen, W. 1980. Purification, subunit structure, and serological analysis of calf thymus ribonuclease H1. J. Biol. Chem. 255:9434-9443.
13. Cazenave, C, C. A. Stein, N. Loreau, N. T. Thuong, and L. M. Neckers. 1989. Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides. Nucleic Acids Res. 17:4255-4261.
14. Chiang, M-Y., H. Chan, M. A. Zounes, S. M. Freier, W. F. Lima, and C. F. Bennett. 1991. Antisense oligonucleotides inhibit ICAM-1 expression by two distinct mechanisms. J. Biol. Chem. 266:18162-18171.
15. Choo, Q.-L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradly, and M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362.
16. Choo, Q.-L., K. H. Richman. J. H. Han, K. Berger, C. Lee, C. Dong, C. Gallegos, D. Coit, A. Medina-Selby, P. J. Barr, A. J. Weiner, D. W. Bradley, G. Kuo, and M. Houghton. 1991. Genetic organization and diversity of the hepatitis C virus. Proc. Natl. Acad. Sci. USA 88:2451-2455.
17. Cowsert, L. M., M. C. Fox, G. Zon, and C. K. Mirabelli. 1993. In vitro evaluation of phosphorothinate oligonucleotides targeted to the E2 mRNA of papilloraavirus: potential treatment for genital warts. Antimicrob. Agents Chemother. 37:171-177.
18. Crooke, S. T. 1992. Therapeutic applications of oligonucleotides. Annu. Rev, Pharmacol. Toxicol. 32:329-376.
19. Crooke, S. T. 1995. Oligonucleotide therapeutics, p. 863-900. In M. E. Wolff (ed.), Burger's medicinal chemistry and drug discovery, 5th ed., vol. 1. Principles and practice. John Wiley & Sons, Inc., New York.
20. Crooke, S. T. 1995. Progress in antisense therapeutics. Hematol. Pathol. 9: 59-72.
21. Crum, C, J. D. Johnson, A. Nelson, and D. Roth. 1988. Complementary oligodeoxynucleotide mediated inhibition of tobacco mosaic virus RNA translation in vitro. Nucleic Acids Res. 16:4569-4581.
22. Cummins, L. Personal communication.
23. Cummins, I, L., S. R. Owens, L. M. Risen, E. A. Lesnik, S. M. Freier, D. McGee, C. J. Guinosso, and P. D. Cook. 1995. Characterization of fully 2′-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. Nucleic Acids Res. 23:2019-2024.
24. Davis, G. L., L. A. Balart, E. R. Schiff, K. Lindsay, H. C. Bodenheimer, Jr., R. P. Perrillo, W. Carey, I. M. Jacobson, J. Payne, and J. L. Dienstag. 1989. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. N. Engl. J. Med. 321:1501-1506.
25. Dean, N. M., R. McKay, T. P. Condon, and C. F. Bennett. 1994. Inhibition of protein kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem. 269:16416-16424.
26. Di Bisceglie, A. M., P. Martin, C. Kassianides, M. Lisker-Melman, L. Murray. J. Waggoner, Z. Goodman, S. M. Banks, and J. H. Hoofnagle. 1989. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized double-blind, placebo-controlled trial. N. Engl. J. Med. 321:1506-1510.
27. Ehrenfeld, E., and B. L. Semler. 1995. Anatomy of the poliovirus internal ribosome entry site, p. 65-83. In P. Sarnow (ed.), Cap-independent translation. Springer-Verlag, Berlin.
28. Freier, S. M. 1993. Hybridization: considerations affecting antisense drugs, p. 67-82. In S. T. Crooke and B. Lebleu (ed.), Antisense research and applications. CRC Press. Boca Raton, Fia.
29. Freier, S. M., R. Kierzek, J. A. Jaeger, N. Sugimoto, M. H. Caruthers, and T. Neilson. 1986. Improved free-energy parameters for predictions of RNA duplex stability. Proc. Natl. Acad. Sci. USA 83:9373-9377.
30. Hoke, G., K. Draper, S. Freier, C. Gonzalez, V. B. Driver, M. C. Zounes, and D. J. Ecker. 1991. Effect of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus. Nucleic Acids Res. 19:5743-5748.
31. Inoue, H., Y. Hayase, S. Iwai, and E. Ohtsuka. 1987. Sequence-dependent hydrolysis of RNA using modified Oligonucleotide splints and RNase H. FEBS Lett. 215:327-330.
32. Kawasaki, A. M., M. D. Casper, S. M. Freier, E. A. Lesnik, M. C. Zounes, L. L. Cummins, C. Gonzalez, and P. D. Cook. 1993. Uniformly modified 2′-deoxy-2′-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J. Med. Chem. 36:831-841.
33. Kulka, M., C. C. Smith, L. Aurelian, R. Fishelevich, K. Meade, P. Miller, and P. O. P. Ts'O. 1989. Site specificity of the inhibitory effects of oligo(nucleo-side methylphlosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4. Proc. Natl. Acad. Sci. USA 86:6868-6872.
34. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 227:680-685.
35. Liu, X., and M. A. Gorovsky. 1993. Mapping the 5′ and 3′ ends of Tetrahymena thermophila mRNAs using RNA ligase mediated amplification of cDNA ends (RLM-RACE). Nucleic Acids Res. 21:4954-4960.
36. Macejak, D. G., and P. Sarnow. 1991. Internal initiation of translation mediated by the 5′ leader of a cellular mRNA. Nature (London) 353:90-94.
37. Marcellin, P., N. Boyer, E. Giostra, C. Degott, A. M. Courouce, F. Degos, H. Coppere, P. Cales, P. Couzigou, and J. P. Benhamou. 1991. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 13:393-397.
38. Martin, P. 1995. Ein neuer Zugang zu 2′-O-alkylribonucleosiden und Eigenschaften deren Oligonucleotide. Helv. Chim. Acta 78:486-504.
39. Monia, B. P., J. F. Johnston, D. J. Ecker, M. A. Zounes, W. F. Lima, and S. M. Freier. 1992. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem. 267:19954-19962.
40. Monia, B. P., E. A. Lesnik, C. Gonzalez, W. F. Lima, D. McGee, C. J. Guinosso, A. M. Kawasaki, P. D. Cook, and S. M. Freier. 1993. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268:14514-14522.
41. Oh, S. K., M. P. Scott, and P. Sarnow. 1992. Homeotic gene antennapedia mRNA contains 5′-noncoding sequences that confer translational initiation by internal ribosome binding. Genes Dev. 6:1643-1653.
42. Simonetti, R. G., M. Cottone, A. Craxi, L. Pagliaro, M. Rapicetta, P. Chionne, and A. Costantino. 1989. Prevalence of antibodies to hepatitis C virus in hepatocellular carcinoma. Lancet ii:1338.
43. Sproat, B. S., A. L. Lanmond, B. Beijer, P. Neuner, and U. Ryder. 1989. Highly efficient chemical synthesis of 2′-O-methyloligoribonucleotides and tetra-biotinylated derivatives: novel probes that are resistant to degradation by RNA or DNA specific nucleases. Nucleic Acids Res. 17:3373-3386.
44. Stein, C. A., and Y.-C. Cheng. 1993. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 261:1004-1012.
45. Tsukiyama-Kohara, K., N. Iizuka, M. Kohara, and A. Nomoto. 1992. Internal ribosome entry site within hepatitis C virus RNA. J. Virol. 66:1476-1483.
46. Ueno, T., T. Miyamura, I. Saito, and K. Mizuno. 1993. Immortalization of differentiated human hepatocytes by a combination of a viral vector and collagen gel culture. Hum. Cell 6:125-135.
47. Uhlmann, E., and A. Peyman. 1990. Antisense oligonucleotides: a new therapeutic principle. Chem. Rev. 90:543-584.
48. Wakita, T., and J. R. Wands. 1994. Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. J. Biol. Chem. 269:14205-14210.
49. Wang, C., S.-Y. Le, and A. Siddiqui. 1995. An RNA pseudoknot is an essential structural element of the internal ribosome entry site located within the hepatitis C virus 5′ noncoding region. RNA 1:526-537.
50. Wang, C., P. Sarnow, and A. Siddiqui. 1993. Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism. J. Virol. 67:3338-3344.
51. Wang, C., P. Sarnow, and A. Siddiqui. 1994. A conserved helical element is essential for internal initiation of translation of hepatitis C virus RNA. J. Virol. 68:7301-7307.
52. Wickstrom, E. 1986. Oligodeoxynucleotide stability in subcellular extracts and culture media. J. Biochem. Biophys. Methods 13:97-102.
53. Zamecnik, P. C., J. Goodchild, Y. Taguchi, and P. S. Sarin. 1986. Inhibition of replication and expression of human T-cell lymphotropic virus type 111 in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc. Natl. Acad. Sci. USA 83:4143-4146.